ArcticZymes Technologies executes contract with consortium for Advanced therapies enzyme project funded by The Research Council of Norway

17 Jun 2024 14:58 CEST

Tromsø, Norway, June 17, 2024 - ArcticZymes Technologies ASA (OSE: AZT) has
today executed a contract with The Research Council of Norway, securing up to
11.8 MNOK for a collaborative project aimed at supporting the advanced therapy
biomanufacturing sector.

This follows a previously announced research grant awarded by the Norwegian
Research Council. The agreements with the Norwegian Research Council and the
project partners, the University of Tromsø - The Arctic University of Norway,
and SINTEF Industri have now been finalized, marking the project's commencement.
The project has been named AdEPT - Advancing Enzymes for Precision Therapeutics
and will run from 2024 through 2027.

In recent years, ArcticZymes Technologies has successfully provided enzymes for
manufacturing viral vectors used in cell and gene therapy, as well as vaccines.
Viral vectors and nucleic acids like RNA and DNA are increasingly utilized in
advanced therapy medicinal products. Enzymes play a crucial role in the
manufacturing, analytics, and quality control of these therapeutic RNAs and
DNAs. However, significant technical challenges remain, including development
costs, commercial scale manufacturing, and sufficient quality for therapeutic
use. The project, AdEPT, aims to address these challenges by developing novel
enzyme solutions for the manufacturing and analysis of therapeutic RNA.

CEO Michael B. Akoh stated: "I am pleased to see that we are executing on our
strategy to build a unique portfolio of enzymes within the advanced therapies
biomanufacturing segment. The collaboration with the University of Tromsø and
SINTEF Industri, and funding from The Research Council of Norway provides an
excellent foundation. I look forward to following the project's progress over
the coming years and witnessing the emergence of new prototypes that can help
realize the potential of the many new therapeutic modalities currently in
development."

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who develop therapeutics, in
vitro diagnostics, and molecular research kit products. Our mission is to make
our customers lives easier by unlocking new solutions to enhance quality of life
and create a more sustainable healthy world.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh  Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who develop therapeutics, in
vitro diagnostics, and molecular research kit products. Our mission is to make
our customers lives easier by unlocking new solutions to enhance quality of life
and create a more sustainable healthy world.  For more information, please visit
the website: www.arcticzymes.com

More information:
Access the news on Oslo Bors NewsWeb site

621715_Grant_award_signed_17062024.pdf